Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations

Ichidai Tanaka; Masahiro Morise; Yuta Kodama; Akira Matsui; Naoya Ozawa; Sachiko Ozone; Daiki Goto; Ayako Miyazawa; Tetsunari Hase; Naozumi Hashimoto; Mitsuo Sato; Yoshinori Hasegawa

doi:10.1016/j.lungcan.2018.11.018

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations

Ichidai Tanaka, Masahiro Morise, Yuta Kodama, Akira Matsui, Naoya Ozawa, Sachiko Ozone, Daiki Goto, Ayako Miyazawa, Tetsunari Hase, Naozumi Hashimoto, Mitsuo Sato, Yoshinori Hasegawa

Research output: Contribution to journal › Letter › peer-review

24 Citations (Scopus)

Original language	English
Pages (from-to)	169-171
Number of pages	3
Journal	Lung Cancer
Volume	127
DOIs	https://doi.org/10.1016/j.lungcan.2018.11.018
Publication status	Published - 01-2019
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2018.11.018

Cite this

@article{8d5917ae288c4bde9e740e2ba7f93c96,

title = "Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations",

author = "Ichidai Tanaka and Masahiro Morise and Yuta Kodama and Akira Matsui and Naoya Ozawa and Sachiko Ozone and Daiki Goto and Ayako Miyazawa and Tetsunari Hase and Naozumi Hashimoto and Mitsuo Sato and Yoshinori Hasegawa",

year = "2019",

month = jan,

doi = "10.1016/j.lungcan.2018.11.018",

language = "English",

volume = "127",

pages = "169--171",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations

AU - Tanaka, Ichidai

AU - Morise, Masahiro

AU - Kodama, Yuta

AU - Matsui, Akira

AU - Ozawa, Naoya

AU - Ozone, Sachiko

AU - Goto, Daiki

AU - Miyazawa, Ayako

AU - Hase, Tetsunari

AU - Hashimoto, Naozumi

AU - Sato, Mitsuo

AU - Hasegawa, Yoshinori

PY - 2019/1

Y1 - 2019/1

UR - http://www.scopus.com/inward/record.url?scp=85059771335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059771335&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2018.11.018

DO - 10.1016/j.lungcan.2018.11.018

M3 - Letter

C2 - 30477806

AN - SCOPUS:85059771335

SN - 0169-5002

VL - 127

SP - 169

EP - 171

JO - Lung Cancer

JF - Lung Cancer

ER -

Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this